Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.07 EUR | +0.07% |
|
-0.50% | -22.70% |
08:56am | Bayer's Prostate Cancer Combo Extends Progression-Free Survival in Late-stage Trial | MT |
08:08am | Bayer's Nubeqa Meets Key Goal in Late-Stage Prostate Cancer Trial | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.70% | 2.79TCr | |
+61.53% | 85TCr | |
+34.02% | 63TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.18% | 30TCr | |
+11.41% | 23TCr | |
+15.35% | 23TCr | |
+15.67% | 18TCr | |
+2.47% | 17TCr |
- Stock Market
- Equities
- BAYN Stock
- News Bayer AG
- Transcript : Bayer Aktiengesellschaft - Special Call